Why the study?
MiR-20a-5p is declined in hearts of diabetic mice, but its effect on diabetic cardiomyopathy remains unknown.
Does miR-20a-5p overexpression improve diabetic cardiomyopathy in preclinical models?
Population
Streptozotocin-induced DCM rat model and high glucose-stimulated H9C2 model of DCM
Comparison
Adenovirus expressing miR-20a-5p treatment
Design
In vivo and in vitro animal and cell study
Authors
Loading...
Supports miR-20a-5p as a target in diabetic cardiomyopathy models; leaves open translation to human therapy.
Does miR-20a-5p overexpression improve diabetic cardiomyopathy in preclinical models?
MiR-20a-5p overexpression ameliorates diabetic cardiomyopathy in preclinical models by inhibiting inflammation, apoptosis, hypertrophy, and fibrosis via the ROCK2/JNK/NF-κB pathway.
Liu et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: